These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20437117)

  • 1. STEPP for the EGFR inhibitor-induced rash--definitely a step in the right direction.
    Coleman S; Jatoi A
    Curr Oncol Rep; 2010 Jul; 12(4):223-5. PubMed ID: 20437117
    [No Abstract]   [Full Text] [Related]  

  • 2. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.
    Lacouture ME; Mitchell EP; Piperdi B; Pillai MV; Shearer H; Iannotti N; Xu F; Yassine M
    J Clin Oncol; 2010 Mar; 28(8):1351-7. PubMed ID: 20142600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of a pre-emptive skin treatment regimen on skin toxicities of anti-epidermal growth factor receptor monoclonal antibodies: more questions than answers.
    Rother M
    J Clin Oncol; 2010 Sep; 28(27):e474; author reply e475-6. PubMed ID: 20585089
    [No Abstract]   [Full Text] [Related]  

  • 4. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
    Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
    Grande R; Narducci F; Bianchetti S; Mansueto G; Gemma D; Sperduti I; Trombetta G; Angelini F; Gamucci T
    Support Care Cancer; 2013 Jun; 21(6):1691-5. PubMed ID: 23314653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing skin toxicities related to panitumumab.
    Bergman H; Walton T; Del Bel R; Seki JT; Rafii A; Xu W; Koren G; Shear N; Krzyzanowska MK; Howell D; Liu G
    J Am Acad Dermatol; 2014 Oct; 71(4):754-9. PubMed ID: 25085331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
    Jatoi A; Thrower A; Sloan JA; Flynn PJ; Wentworth-Hartung NL; Dakhil SR; Mattar BI; Nikcevich DA; Novotny P; Sekulic A; Loprinzi CL
    Oncologist; 2010; 15(9):1016-22. PubMed ID: 20798191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.
    Resch G; Schaberl-Moser R; Kier P; Kopetzky G; Scheithauer W; Sliwa T; Greil R; Nösslinger T; Mayrbäurl B; Thaler J
    Ann Oncol; 2011 Feb; 22(2):486-7. PubMed ID: 21239398
    [No Abstract]   [Full Text] [Related]  

  • 9. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer.
    Eng C
    Nat Rev Clin Oncol; 2009 Apr; 6(4):207-18. PubMed ID: 19333227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.
    Pinto C; Barone CA; Girolomoni G; Russi EG; Merlano MC; Ferrari D; Maiello E; ;
    Oncologist; 2011; 16(2):228-38. PubMed ID: 21273511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
    Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In search of rigorous data on how to palliate the EGFR inhibitor-induced rash.
    Jatoi A
    Oncology (Williston Park); 2009 Feb; 23(2):196, 198. PubMed ID: 19323303
    [No Abstract]   [Full Text] [Related]  

  • 13. Cetuximab severe cutaneous toxicity… a gateway for bacteremia: case report.
    Soueidy C; Skaff S; Stephan F; Kattan J
    Anticancer Drugs; 2023 Jan; 34(1):187-189. PubMed ID: 36539371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients.
    Yamada M; Iihara H; Fujii H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Anticancer Res; 2015 Nov; 35(11):6175-81. PubMed ID: 26504047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
    Van Cutsem E; Siena S; Humblet Y; Canon JL; Maurel J; Bajetta E; Neyns B; Kotasek D; Santoro A; Scheithauer W; Spadafora S; Amado RG; Hogan N; Peeters M
    Ann Oncol; 2008 Jan; 19(1):92-8. PubMed ID: 17785764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials.
    Petrelli F; Borgonovo K; Barni S
    Target Oncol; 2013 Sep; 8(3):173-181. PubMed ID: 23321777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panitumumab: a review of its use in metastatic colorectal cancer.
    Keating GM
    Drugs; 2010 May; 70(8):1059-78. PubMed ID: 20481659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of panitumumab into the treatment of colorectal cancer.
    Gravalos C; Cassinello J; García-Alfonso P; Jimeno A
    Crit Rev Oncol Hematol; 2010 Apr; 74(1):16-26. PubMed ID: 19616446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
    Snyder LC; Astsaturov I; Weiner LM
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S71-80. PubMed ID: 16336752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.